まとめ
イブプロフェンとアスピリンは,リウマチ性関節炎の痛み緩和に類似した効果を示しました. しかし,イブプロフェンは,アスピリンと比較して,より良く耐えられ,胃腸の問題と副作用が少なくなりました.
科学分野:
- 薬理学 薬理学とは
- レウマトロジーの病理学
- クリニック・トライアル 臨床試験
背景:
- イブプロフェンは,非ステロイド薬であり,鎮痛剤,発熱剤,抗炎症効果があります.
- 最近,米国で抗関節炎療法として承認されました.
研究 の 目的:
- リウマチ性関節炎患者のイブプロフェンとアスピリンの有効性と耐性を比較する.
- 両薬とも関連した副作用や胃腸疾患を評価する.
主な方法:
- リウマチ性関節炎の患者885人を対象とした1年間のダブルブラインド多臨床試験です.
- 患者は,1日800〜1,600mgのイブプロフェンまたは3〜6gmのアスピリンを投与された.
主要な成果:
- イブプロフェンは,関節炎の症状を和らげるのにアスピリンと同等の有効性を示しました.
- イブプロフェンは,特に胃腸疾患に関して,著しく高い耐性を示した.
- 副作用の離脱率は,イブプロフェンでは7%,アスピリンでは16%でした.
- 胃腸の症状は,イブプロフェン群の17%,アスピリン群の31%に比べて有りました.
結論:
- イブプロフェンは,リウマチ性関節炎の管理のために,アスピリンに代わって,よく耐える,効果的な代替品です.
- イブプロフェンの改善された胃腸受容性は,長期的な関節炎管理に重要な利点を提供します.
関連する概念動画
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...